{"entity":{"id":"nct06605222","kind":"trial","name":"A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SHR-7787 injection in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","summary":"A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06605222 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 201 participants planned, started 2024-10-04 and due to reach its primary completion in 2026-07-31. Interventions recorded: SHR-7787 injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06605222","url":"https://clinicaltrials.gov/study/NCT06605222"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06605222","phase":"1/2","setting":"A Phase I/II, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-7787 in Patients With Advanced Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","enrolled":201,"outcomes":[]},"route":"/trials/nct06605222/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}